These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 26165016)

  • 1. [Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
    Pan Y; Wen S; Tian J; Lyu Z; Du Z; Yan L
    Zhonghua Er Ke Za Zhi; 2015 Mar; 53(3):194-7. PubMed ID: 26165016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Efficacy and Safety of Flumatinib in the Treatment of Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase].
    Li Q; Jing L; Wu PQ; Han LY; Xing HY; Huang CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia].
    Ye YF; Lyu XM; Li HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):456-461. PubMed ID: 33812415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
    J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
    Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
    Zhang LQ; Zheng J; Chen ZP; Li SD; Ma J; Wu RH
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):113-117. PubMed ID: 30695885
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
    Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
    Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
    Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
    Millot F; Baruchel A; Guilhot J; Petit A; Leblanc T; Bertrand Y; Mazingue F; Lutz P; Vérité C; Berthou C; Galambrun C; Bernard F; Yacouben K; Bordigoni P; Edan C; Reguerre Y; Couillault G; Méchinaud F; Cayuela JM; Guilhot F
    J Clin Oncol; 2011 Jul; 29(20):2827-32. PubMed ID: 21670449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
    Campiotti L; Suter MB; Guasti L; Piazza R; Gambacorti-Passerini C; Grandi AM; Squizzato A
    Eur J Cancer; 2017 May; 77():48-56. PubMed ID: 28365527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].
    Li YY; Wang CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):14-19. PubMed ID: 38387894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.